Hims & Hers Health is partnering with Novo Nordisk to expand access to FDA-approved GLP-1 weight loss medications through its U.S. platform.
The agreement includes Ozempic injections in 0.5-, 1- and 2-milligram doses, as well as Wegovy injections in 1.7- and 2.4-milligram doses and Wegovy tablets in 1.5-, 4-, 9- and 25-milligram strengths, according to a March 9 news release. The products will be available later this month.
Hims & Hers said it will stop advertising compounded GLP-1 offerings and limit access to those medications to patients for whom FDA-approved alternatives are not clinically appropriate.
The partnership follows a legal dispute between the companies. In early February, Hims & Hers began selling a compounded version of Novo’s newly approved Wegovy pill for $99 per month. Novo filed a patent infringement lawsuit the same day, and HHS referred the company to the Justice Department over potential violations of federal drug law. Hims & Hers removed the product days later.
Novo is now dismissing its lawsuit without prejudice. The partnership revives a 2025 collaboration that dissolved within months amid disagreements over compounded drugs.
FDA Commissioner Marty Makary, MD, congratulated both parties March 9 on X, saying the deal maintains affordable pricing, limits compounded drugs to FDA-compliant cases, and follows recent action by the agency. He called the outcome “a win for the American people.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
